EIM
CTMX icon

Essex Investment Management’s CytomX Therapeutics CTMX Stock Holding History

Essex Investment Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-21,969
Closed -$502K – 412
2018
Q2 		$502K Buy
+21,969
New +$561K 0.06% 291

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Essex Investment Management's CTMX Position: Q3 2018 in Review

Essex Investment Management sold out of CytomX Therapeutics (CTMX) in Q3 2018, closing a stake of 21,969 shares — an estimated $502K sold.

Essex Investment Management first reported a position in CTMX in Q2 2018 and held it in 1 quarter. The position peaked at $502K in Q2 2018. 122 funds tracked by Wall St. Rank hold CTMX as of Q3 2018.

  • Essex Investment Management reported no remaining CytomX Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Essex Investment Management sold 21,969 CytomX Therapeutics shares in Q3 2018, an estimated $502K.
  • Essex Investment Management first reported a position in CytomX Therapeutics in Q2 2018 and held it in 1 quarter.
  • Essex Investment Management's CytomX Therapeutics position peaked at $502K in Q2 2018.
  • 122 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2018.

Based on Essex Investment Management's 13F filing for Q3 2018, filed 16 Oct 2018.